eISSN: 2450-4459
ISSN: 2450-3517
Lekarz POZ
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
4/2020
vol. 6
 
Share:
Share:
more
 
 
abstract:
Review article

Effective combination of chronic heart failure and chronic obstructive pulmonary disease pharmacotherapy – is it possible?

Anna Wizner
1
,
Mariola Szulik
1, 2

1.
Śląskie Centrum Chorób Serca w Zabrzu
2.
Akademia WSB w Dąbrowie Górniczej
Online publish date: 2020/11/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The article presents the modern pharmacotherapy of coincident two common diagnoses: chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF). From the clinical point of view, the main doubts and controversies are related to β-blockers. Non-selective β-blockers decrease FEV1. The fears of the use of cardioselective β-blockers are unjustified: retrospective observations indicate that they have a neutral or advantageous effect on the decrease of COPD exacerbation frequency. β-blockers may prevent arrhythmogenic and ischaemic incidents during the intensification of inhaled β2-agonist therapy. The highest cardioselectivity is represented by nebivolol. It is deemed that cholinolytics and β2-agonists with prolonged activity cause ventricular and supraventricular arrythmias. However – attention should be paid to other coexisting arrhythmogenic factors: the erroneous use of theophylline, pulmonary embolism, hypokalaemia, hypomagnesaemia, hypoxaemia, chronic kidney disease, and the COPD exacerbation itself. At last magnesium citrate – the element recommended both by heart and lung specialists.
keywords:

heart failure, chronic obstructive pulmonary disease, pharmacotherapy, β-adrenergic agents

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe